Nicholas C Richardson

Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.

K. Norga, K. Wilner, Martha Donoghue, 2021, European journal of cancer.

FDA’s Oncology Center for Excellence Pilots Project Orbis: A framework for concurrent submission and review of oncology products among international partners.

K. Goldberg, R. Pazdur, Y. Kasamon, 2020 .

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

R. Pazdur, Y. Kasamon, G. Blumenthal, 2019, The oncologist.

FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma

R. Pazdur, G. Reaman, Y. Kasamon, 2022, Pediatric blood & cancer.

FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients

R. Pazdur, G. Reaman, A. Farrell, 2020, Pediatric blood & cancer.

The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.

R. Pazdur, Y. Kasamon, N. Gormley, 2022, The Lancet. Oncology.

FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

R. Pazdur, Y. Kasamon, M. Theoret, 2021, The oncologist.